Cadila Pharmaceuticals Limited

Cadila Pharmaceuticals Limited, established in 1951 by Indravadan A. Modi, is a prominent Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. The company specializes in the development and manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories. Cadila Pharmaceuticals operates as a privately held entity, with its corporate identification number (CIN) being U24231GJ1991PLC015132. As of March 2026, the company employs approximately 6,096 individuals. The official website for Cadila Pharmaceuticals is www.cadilapharma.com.

In the fiscal year ending March 31, 2024, Cadila Pharmaceuticals reported an annual revenue of $433.44 million USD and a net profit of $11.8 million USD. The company's authorized capital stands at ₹1,206.5 million, with a paid-up capital of ₹800.1 million. Cadila Pharmaceuticals has a significant presence in over 100 countries, with a workforce exceeding 9,000 employees globally.

Cadila Pharmaceuticals operates multiple manufacturing facilities to support its extensive product portfolio. The primary formulation manufacturing plant is located in Dholka, Gujarat, India, covering over 100 acres and holding USFDA approval. Another formulation facility is situated in Samba, Jammu & Kashmir, India, producing a range of dosage forms. Additionally, the company has an active pharmaceutical ingredient (API) manufacturing unit in Ankleshwar, Gujarat, India, which is USFDA-certified. Internationally, Cadila Pharmaceuticals has a formulation manufacturing facility in Addis Ababa, Ethiopia, which complies with WHO cGMP standards.

The leadership of Cadila Pharmaceuticals is headed by Rajiv Indravadan Modi, who serves as the Chairman and Managing Director. Under his guidance, the company has expanded its global footprint and diversified its product offerings. The Board of Directors includes key figures such as Ramesh Ratilal Choksi, who holds the position of Whole-Time Director, and Girdhar Prem Balwani, an Independent Director. The company's leadership team is committed to upholding high standards of corporate governance and ethical business practices.

Cadila Pharmaceuticals has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities in Dholka and Ankleshwar, Gujarat, are USFDA-approved, enabling the export of pharmaceutical formulations to the U.S. market. The facility in Dholka also meets stringent quality standards, facilitating access to European and UK markets. The company's commitment to quality is further demonstrated by its WHO cGMP-compliant facility in Addis Ababa, Ethiopia, which supports its operations in Africa. These regulatory approvals underscore Cadila Pharmaceuticals' dedication to maintaining high manufacturing standards and ensuring the safety and efficacy of its products in international markets.

Cadila Pharmaceuticals has strategically expanded its footprint in emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's formulation manufacturing facility in Addis Ababa, Ethiopia, serves as a gateway to the African market, providing access to a region with growing healthcare needs. While specific details regarding operations in Latin America and Southeast Asia are limited, Cadila Pharmaceuticals' global outreach and commitment to innovation suggest potential growth opportunities in these regions. The company's adherence to international quality standards, such as WHO cGMP compliance, positions it favorably to meet the demands of emerging markets seeking high-quality pharmaceutical products.

Cadila Pharmaceuticals has adopted a diversified geographic strategy to mitigate concentration risk and capitalize on global market opportunities. The company's manufacturing facilities in Gujarat, India, and Addis Ababa, Ethiopia, enable it to serve both domestic and international markets effectively. By maintaining a presence in multiple regions, Cadila Pharmaceuticals can leverage local market knowledge and adapt to regional regulatory requirements. This strategic diversification enhances the company's resilience and positions it to respond proactively to global healthcare trends and demands.

Cadila Pharmaceuticals' manufacturing facilities in Dholka and Ankleshwar, Gujarat, are registered with the U.S. Food and Drug Administration (FDA), allowing the company to export pharmaceutical formulations to the U.S. market. The Dholka facility holds USFDA approval, ensuring compliance with stringent manufacturing standards required for the U.S. market. The Ankleshwar facility is also USFDA-certified, indicating adherence to quality standards necessary for exporting APIs to the U.S. These FDA registrations reflect Cadila Pharmaceuticals' commitment to maintaining high-quality manufacturing processes and meeting the regulatory requirements of the U.S. market.

Cadila Pharmaceuticals' manufacturing facility in Addis Ababa, Ethiopia, is compliant with the World Health Organization's Good Manufacturing Practices (WHO cGMP), ensuring that the company meets international standards for pharmaceutical manufacturing. While specific details regarding EU GMP certification are not provided, the company's adherence to WHO cGMP standards suggests a commitment to maintaining high-quality manufacturing processes that align with international regulatory expectations.

Cadila Pharmaceuticals operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facilities in Gujarat are licensed by the CDSCO, ensuring compliance with national pharmaceutical manufacturing standards. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not provided; however, the company's adherence to CDSCO regulations indicates a commitment to maintaining high-quality manufacturing processes and meeting the regulatory requirements for domestic and international markets.

In 2014, the U.S. Food and Drug Administration (FDA) issued a warning letter to Cadila Pharmaceuticals regarding manufacturing practice discrepancies at its Ankleshwar facility in Gujarat. Similar notices were issued in 2016 and 2019, highlighting the FDA's increased scrutiny of generic drug manufacturers. These incidents underscore the importance of maintaining stringent manufacturing practices to comply with international regulatory standards.

Cadila Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share comparisons are not provided, the company's diverse product portfolio and global manufacturing capabilities position it as a significant competitor in the market. The company's focus on innovation and adherence to international quality standards enable it to compete effectively across various therapeutic categories and geographic regions.

Cadila Pharmaceuticals' key differentiators include its strong emphasis on research and development, leading to first-in-the-world innovations in areas such as lung cancer, tuberculosis, cardiovascular diseases, and gastroenterology. The company's state-of-the-art manufacturing facilities, compliant with international standards like USFDA, European Union, MHRA UK, WHO Geneva, and TGA Australia, further distinguish it in the market. Additionally, Cadila Pharmaceuticals' global outreach, with operations in over 100 countries and a workforce of more than 9,000 employees, enhances its competitive advantage.

Cadila Pharmaceuticals maintains a strategic focus on innovation and research, with a presence in over 45 therapeutic areas across 12 specialties, including cardiovascular, gastrointestinal, analgesics, hematinics, anti-infectives, antibiotics, respiratory agents, antidiabetics, and immunologicals. The company's commitment to ethical business practices and high-quality manufacturing standards positions it favorably in the global pharmaceutical market. Looking ahead, Cadila Pharmaceuticals is well-positioned to leverage its strengths in research and development, manufacturing capabilities, and global presence to drive future growth and innovation.

Cadila Pharmaceuticals has a track record of consistent export volume, with a total export value of $20.2 million USD and 908 shipments across 15 products in 11 therapeutic categories. The company's portfolio concentration is notable, with the top five products accounting for 57.6% of total exports. This concentration includes products such as Verapamil, Mebendazole, Folic, Domperidone, and Ethambutol, which are leaders in their respective markets.